Jump to content

Essential thrombocythemia

From Wikipedia, the free encyclopedia
(Redirected from Hemorrhagic thrombocythemia)
Essential thrombocythemia
Other namesEssential thrombocythaemia, essential thrombocytosis, primary thrombocytosis
Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia.
SpecialtyHematology Edit this on Wikidata
SymptomsFatigue, insomnia, migraines, headache, and dizziness.[1]
ComplicationsThrombosis, transient ischemic attack, acute coronary syndrome, Budd-Chiari syndrome.[1]
CausesOverproduction of hematopoietic cells, genetic mutations.[1]
Diagnostic methodClinical criteria.
Differential diagnosisChronic myelogenous leukemia, myelodysplastic syndrome, polycythemia vera, primary myelofibrosis, secondary thrombocytosis.[1]
TreatmentLow-dose aspirin, plateletpheresis, cytoreductive therapy.[1]
PrognosisMedian survival is 18 years.[1]
Frequency0.6-2.5/100,000 cases per year.[2]

In hematology, essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.[3] It may, albeit rarely, develop into acute myeloid leukemia or myelofibrosis.[3] It is one of the blood cancers wherein the bone marrow produces too many white or red blood cells, or platelets.[3]

Signs and symptoms

[edit]

Most people with essential thrombocythemia are without symptoms at the time of diagnosis, which is usually made after noting an elevated platelet level on a routine complete blood count (CBC).[4] The most common symptoms are bleeding (due to dysfunctional platelets), blood clots (e.g., deep vein thrombosis or pulmonary embolism), fatigue, headache, nausea, vomiting, abdominal pain, visual disturbances, dizziness, fainting, and numbness in the extremities; the most common signs are increased white blood cell count, reduced red blood cell count, and an enlarged spleen.[4][5][6]

Cause

[edit]

In ET, megakaryocytes are more sensitive to growth factors.[7] Platelets derived from the abnormal megakaryocytes are activated, which, along with the elevated platelet count, contributes to the likelihood of forming blood clots.[8] The increased possibility of bleeding when the platelet count is over 1 million is due to von Willebrand factor (vWF) sequestration by the increased mass of platelets, leaving insufficient vWF for platelet adhesion.[8] A mutation in the JAK2 kinase (V617F) is present in 40–50% of cases and is diagnostic if present.[3][8] JAK2 is a member of the Janus kinase family.[3][8]

In 2013, two groups detected calreticulin mutations in a majority of JAK2-negative/MPL-negative patients with essential thrombocythemia and primary myelofibrosis, which makes CALR mutations the second most common in myeloproliferative neoplasms. All mutations (insertions or deletions) affected the last exon, generating a reading frame shift of the resulting protein, that creates a novel terminal peptide and causes a loss of endoplasmic reticulum KDEL retention signal.[9][10]

There are three known genetic mutations that cause ET. The most common genetic mutation is a JAK2 mutation. Roughly 50% of the population of ET patients have this mutation. The JAK 2 gene signals a protein that promotes the growth of cells. The protein is part of a signaling pathway called the JAK/STAT pathway. The JAK2 protein controls the production of blood cells from hematopoietic stem cells which are located in the bone marrow and can eventually become platelets, red blood cells or white blood cells. Specifically in ET, a JAK2 mutation is acquired rather than inherited. The most common JAK2 mutation is V617F which is the replacement of a valine amino acid with phenylalanine amino acid at the 617 position, hence the name V617F. This mutation results in the JAK2 protein constantly being turned on, which leads to the overproduction of abnormal blood cells, in ET it is platelets or megakaryocytes. There is also another JAK2 mutation found in exon 12, however much less common.

There is also a small number of people who have a different mutation called CALR, which is abbreviated from calreticulin. CALR is a protein found in the endoplasmic reticulum (ER). Its purpose is to maintain calcium homeostasis and control protein folding. There are three parts to CALR including an amino acid domain, a proline rich P-domain, and a carboxyl domain. All of these parts facilitate the function of CALR. CALR mutation is caused by insertions or deletions of amino acids in exon 9 that cause a reading shift, which then leads to the formation of a novel C terminus. There are two common types of CALR mutations, type 1 and type 2. Type 1 mutations are a 52-bp deletion and type 2 mutations are a 5-bp insertion. In type 1 mutations, the negativle charged amino acids in the CALR C terminus are completely eliminated, and in the type 2 mutations, roughly half are eliminated. There are other mutations involving CALR, however these two are the most common.[11]

Lastly, the least common mutation found in patients with ET are MPL mutations. The MPL gene is responsible for making thrombopoeitin receptor proteins which promote the growth and division of cells. This receptor protein is vital in producing platelets. There are various MPL mutations, but most typical are point mutations that cause amino acid changes. The MPL mutation activates the thrombopoeitin receptor despite the absence of the ligand. This causes the constant proliferation of cells.[12]

Diagnosis

[edit]

The following revised diagnostic criteria for essential thrombocythemia were proposed in 2005.[13] The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6.[14] The criteria are as follows:[14]

  • A1. Platelet count > 400 × 103/μL for at least 2 months.
  • A2. Acquired V617F JAK2 mutation present
  • B1. No cause for a reactive thrombocytosis
    • normal inflammatory indices
  • B2. No evidence of iron deficiency
    • stainable iron in the bone marrow or normal red cell mean corpuscular volume
  • B3. No evidence of polycythemia vera
    • hematocrit < midpoint of normal range or normal red cell mass in presence of normal iron stores
  • B4. No evidence of chronic myeloid leukemia
  • B5. No evidence of myelofibrosis
    • no collagen fibrosis and ≤ grade 2 reticulin fibrosis (using 0–4 scale)
  • B6. No evidence of a myelodysplastic syndrome
    • no significant dysplasia
    • no cytogenetic abnormalities suggestive of myelodysplasia

Treatment

[edit]

Indications

[edit]

Not all those affected will require treatment at presentation.[15][16][17] Patients are usually designated as having a low or high risk of bleeding or developing blood clots based on their age, medical history, blood counts and their lifestyles. Low risk individuals are usually treated with aspirin, whereas those at high risk are treated with hydroxycarbamide, interferon-α or anagrelide).[3][15][16][17] Currently unapproved but in late-stage clinical trials (NCT04254978) are agents that lower platelets such as bomedemstat.

Agents

[edit]

Hydroxycarbamide, interferon-α and anagrelide can lower the platelet count. Low-dose aspirin is used to reduce the risk of blood clot formation unless the platelet count is very high, where there is a risk of bleeding from the disease, and hence this measure would be counter-productive as aspirin-use increases the risk of bleeding.[3][15][16][17]

The PT1 study compared hydroxyurea plus aspirin to anagrelide plus aspirin as initial therapy for ET. Hydroxyurea treated patients had a lower incidence of arterial thrombosis, lower incidence of severe bleeding and lower incidence of transformation to myelofibrosis, but the risk of venous thrombosis was higher with hydroxycarbamide than with anagrelide. It is unknown whether the results are applicable to all ET patients.[3][15][16][17] In people with symptomatic ET and extremely high platelet counts (exceeding 1 million), plateletpheresis can be used to remove platelets from the blood to reduce the risk of thrombosis.[18]

Prognosis

[edit]

Essential thrombocythemia is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events.[15] However, well-documented medical regimens can reduce and control the number of platelets, which reduces the risk of these thrombotic or hemorrhagic events. The lifespan of a well-controlled ET person is well within the expected range for a person of similar age but without ET.[15] ET is the myeloproliferative neoplasm least likely to progress to acute myeloid leukemia.[19]

Epidemiology

[edit]

The incidence of ET is 0.6-2.5/100,000 per year, the median age at onset is 65–70 years and it is more frequent in females than in males.[2] The incidence in children is 0.09/100,000 per year.[2]

Pregnancy

[edit]

Hydroxycarbamide and anagrelide are contraindicated during pregnancy and nursing.[20] Essential thrombocythemia can be linked with a three-fold increase in risk of miscarriage.[2] Throughout pregnancy, close monitoring of the mother and fetus is recommended.[20] Low-dose low molecular weight heparin (e.g. enoxaparin) may be used.[20] For life-threatening complications, the platelet count can be reduced rapidly using plateletpheresis, a procedure that removes platelets from the blood and returns the remainder to the patient.[20]

[edit]

Jill Kaplan, the female protagonist of The Pajama Diaries comic strip was diagnosed with essential thrombocythemia.[21]

References

[edit]
  1. ^ a b c d e f Ashorobi, Damilola; Gohari, Pouyan (August 6, 2023). Essential Thrombocytosis. Treasure Island (FL): StatPearls Publishing. PMID 30969531 – via PubMed.
  2. ^ a b c d Fabris, F; Randi, ML (October 2009). "Essential thrombocythemia: past and present". Internal and Emergency Medicine. 4 (5): 381–8. doi:10.1007/s11739-009-0284-x. PMID 19636672. S2CID 43185338.
  3. ^ a b c d e f g h Beer, PA; Green, AR (2009). "Pathogenesis and management of essential thrombocythemia". Hematology. 2009: 621–628. doi:10.1182/asheducation-2009.1.621. PMID 20008247.
  4. ^ a b Fu, R; Zhang, L; Yang, R (November 2013). "Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment". British Journal of Haematology. 163 (3): 295–302. doi:10.1111/bjh.12530. PMID 24032343. S2CID 10880402.
  5. ^ Frewin, R; Dowson, A (October 2012). "Headache in essential thrombocythaemia". International Journal of Clinical Practice. 66 (10): 976–983. doi:10.1111/j.1742-1241.2012.02986.x. PMC 3469735. PMID 22889110.
  6. ^ Tefferi, A (March 2011). "Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management". American Journal of Hematology. 86 (3): 292–301. doi:10.1002/ajh.21946. PMID 21351120. S2CID 205293800.
  7. ^ Branehog I, Ridell B, Swolin B, Weinfeld A (1975). "Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythaemia and allied diseases". Scand. J. Haematol. 15 (5): 321–32. doi:10.1111/j.1600-0609.1975.tb01087.x. PMID 1060175.
  8. ^ a b c d Vannucchi, AM (June 2010). "Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia". Internal and Emergency Medicine. 5 (3): 177–84. doi:10.1007/s11739-009-0319-3. PMID 19789961. S2CID 510829.
  9. ^ Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (Dec 2013). "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2". The New England Journal of Medicine. 369 (25): 2391–405. doi:10.1056/NEJMoa1312542. PMC 3966280. PMID 24325359.
  10. ^ Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (Dec 2013). "Somatic mutations of calreticulin in myeloproliferative neoplasms". The New England Journal of Medicine. 369 (25): 2379–90. doi:10.1056/NEJMoa1311347. PMID 24325356. S2CID 14787432.
  11. ^ Prins, Daniel; González Arias, Carlos; Klampfl, Thorsten; Grinfeld, Jacob; Green, Anthony R. (February 2020). "Mutant Calreticulin in the Myeloproliferative Neoplasms". HemaSphere. 4 (1): e333. doi:10.1097/HS9.0000000000000333. ISSN 2572-9241. PMC 7000472. PMID 32382708.
  12. ^ Guglielmelli, Paola; Calabresi, Laura (2021), "The MPL mutation", International Review of Cell and Molecular Biology, 365, Elsevier: 163–178, doi:10.1016/bs.ircmb.2021.09.003, ISBN 978-0-323-89939-0, PMID 34756243, retrieved 2024-05-07
  13. ^ Campbell PJ, Green AR (2005). "Management of Polycythemia Vera and Essential Thrombocythemia" (PDF). Hematology. 2005: 201–8. doi:10.1182/asheducation-2005.1.201. PMID 16304381.
  14. ^ a b Vardiman, JW; Thiele, J; Arber, DA; Brunning, RD; Borowitz, MJ; Porwit, A; Harris, NL; Le Beau, MM; Hellström-Lindberg, E; Tefferi, A; Bloomfield, CD (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes" (PDF). Blood. 114 (5): 937–51. doi:10.1182/blood-2009-03-209262. PMID 19357394. S2CID 3101472.[permanent dead link‍]
  15. ^ a b c d e f Cervantes, F (2011). "Management of Essential Thrombocythemia". Hematology. 2011: 215–21. doi:10.1182/asheducation-2011.1.215. PMID 22160037. S2CID 18862829.
  16. ^ a b c d Birgegård, G (July 2013). "Pharmacological management of essential thrombocythemia". Expert Opinion on Pharmacotherapy. 14 (10): 1295–306. doi:10.1517/14656566.2013.797408. PMID 23668666. S2CID 11357000.
  17. ^ a b c d Tefferi, A; Barbui, T (August 2013). "Personalized management of essential thrombocythemia-application of recent evidence to clinical practice". Leukemia. 27 (8): 1617–20. doi:10.1038/leu.2013.99. PMC 3740400. PMID 23558521.
  18. ^ Boddu, Prajwal; Falchi, Lorenzo; Hosing, Chitra; Newberry, Kate; Bose, Prithviraj; Verstovsek, Srdan (2017-07-01). "The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review". Leukemia Research. 58: 14–22. doi:10.1016/j.leukres.2017.03.008. ISSN 0145-2126. PMC 5466892. PMID 28380402.
  19. ^ "Essential Thrombocythemia". The Lecturio Medical Concept Library. Retrieved 22 July 2021.
  20. ^ a b c d Valera, MC; Parant, O; Vayssiere, C; Arnal, JF; Payrastre, B (October 2011). "Essential thrombocythemia and pregnancy". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 158 (2): 141–7. doi:10.1016/j.ejogrb.2011.04.040. PMID 21640467.
  21. ^ "The Pajama Diaries".
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Essential_thrombocythemia&oldid=1232351927"